Cytiva

Cytiva helps the biopharma industry reduce Scope 3 emissions with strategies such as embedding ecodesign principles across our product portfolio and advancing process intensification approaches. Through the use of primary emissions data, we empower manufacturers to make smarter, data-driven sustainability decisions across the entire the value chain.

This presentation examines evolving therapeutic antibody processes. Processing of conventional mAbs continues to mature, while new chromatography approaches are required for multispecifics and fragments—as a one-size-fits-all strategy has become outdated. Optimizing capture requires selecting processes based on the target molecule, development stage, scale-up plans, and budgets. Moreover, antibody variants are challenged with aggregation and product-related impurities. We will evaluate strategies focused on resin selection, operation mode, and process conditions to boost purity, yield, and productivity, including new protein A resins.